Cell and Gene Manufacturing and Logistics

  1. Design Scalable Downstream Processes With Practical Strategies 5/11/2026

    Downstream purification is becoming more complex as new modalities enter development. Learn how advanced analytics and chromatography strategies can support scalable, confident process development.

  2. Can A Biotech Create A CDMO Market? 5/11/2026

    Can a biotech create a CDMO market? GeoVax, an infectious disease/oncology biotech, may have just done so. David Dodd, CEO, believes we should all concentrate more on whether the outsourcing model can align with evolving technology platforms. Both sponsors and CDMOs may need to change things up.

  3. Reducing Inventory Errors In Clinical Trials 5/8/2026

    Can a digital double-check save your trial from data errors? How does verifying shipments at receipt slash inventory mistakes? Learn to protect protocol integrity and patient safety.

  4. Cell And Gene Therapies: The Emerging Reality For Scalable Market Readiness 5/8/2026

    Mainstream biopharma’s commercialization playbook isn’t working for cell and gene therapies. Orgs that invest in scalable platforms (and more) will see better success.

  5. 9 Logistics And Distribution Recommendations For CGTs 5/6/2026

    Cell and gene therapy commercialization requires tailored logistics strategies. Explore nine recommendations covering site readiness, reimbursement gaps, packaging, testing, and coordination.

  6. Building Integrated cGMP Systems for Autologous Cell Therapies with MassGen's Tatyana Matveeva, Ph.D. 5/6/2026

    In episode 128, Host Erin Harris talks to Tatyana Matveeva, Ph.D., Director of cGMP Operations at George A. "Doc" Lopez, MD Laboratory for Regenerative Cell Therapy, Harvard Medical School and Massachusetts General Hospital, about leading cGMP operations within an integrated ecosystem at Harvard Medical School and Massachusetts General Hospital, where manufacturing, research, and neurosurgery coexist.

  7. Why Your MES RFP Is Failing Before It Starts 5/6/2026

    Many manufacturing execution system requests for proposals fail. Not because vendors cannot deliver or the tech is immature, but because the requirements are written backward.

  8. Rapid Selection Of High-Performance CHO Basal And Feed Media 5/5/2026

    A CHO-S bispecific antibody program needed a better basal and feed media combination. Learn how the screening of 180 conditions in 12 weeks identified one that delivered 38% higher titers.

  9. Advancing Your Protein 5/5/2026

    Examine how a CMDO with extensive experience can deliver efficient and high-yielding custom protein manufacturing, supporting clients throughout the entire protein development process.

  10. Advancing CRISPR-Based Therapeutic Development 5/5/2026

    A CDMO that manufactures nucleases at research and cGMP grades can eliminate the need for custom manufacturing runs, simplify the transition to clinical application, and reduce regulatory paperwork.